Accugenix, Inc.
FDA-registered and cGMP compliant, we are the world's foremost provider of leading-edge technologies for microbial identification and characterization services. We challenge you to find a contract lab or purchased system that provides both quality results and a greater return on your investment.
AccuPRO-ID is Significantly More Accurate in Bacterial Identifications than the VITEK®2 Compact: Case Study Evaluations
Accurate classification of unknown bacterial isolates is an essential first step in understanding the impact organisms have on an environmental monitoring program and product safety. In two separate blinded studies, Accugenix, Inc. evaluated the accuracy of reported identifications from the AccuPRO-ID™ method to the results from the bioMérieux VITEK®2 Compact. The data clearly show that the AccuPRO-ID service from Accugenix is significantly more accurate than the VITEK®2, leading to more confidence in the EM information and allowing for more effective trending and tracking in a production facility. The microbial identifications generated by the VITEK®2 were performed independently by our clients. All results were compared to Accugenix’s 16S rDNA sequencing to determine the accuracy between methods.
Despite high confidence percentage match factors, there was no correlation to the accuracy of the results. This combination of missing database entries and incorrect identifications by the VITEK®2 make it nearly impossible to accurately track and trend in a manufacturing environment.
Download the complete study: The AccuPRO-ID Solution from Accugenix, Inc. Click here
Considering outsourcing? Click here for a free financial analysis.
Contact Info: Missy Ruch
missyruch@accugenix.com
Accugenix, Inc.
223 Lake Drive
Newark, DE 19702
+1.302.294.8511
www.accugenix.com
Ulrich Herber, Ph.D., Managing Director, GmbH
ulrichherber@accugenix.com
Accugenix, GmbH
+49 (0)621 3709 556
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
The Role of Forced Degradation in Method Development, Manufacturability, and CMC Strategy
April 28th 2025Forced degradation studies are critical in biologics development, particularly for monoclonal antibodies (mAbs). These studies simulate long-term environmental stressors to uncover degradation pathways and ensure the stability of critical quality attributes (CQAs), aiding in robust chemistry, manufacturing, and controls (CMC) strategies and regulatory compliance.
